Ehave, Psychedelic Stock Review

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
Hea;thLynked, Biotech Stock Review

Up 191%, HealthLynked (HLYK) Reporting Decent Numbers.

Up as much as 417% from where we added it to the Watch List, the Company continues to report increasing revenues while...
@alanliverin

Bitcoin $30,000. Time to Bargain Hunt? Read This First.

The Bit Short: Inside Crypto’s Doomsday Machine Scary article on Tether/Bitcoin posted on...
Internet Stock Review, Draganfly

Meet Draganfly (DFLYF) the Tesla of Drones.

A New Leader In The Drone Industry Emerges US Government Bans Chinese Drones Surprise...
CB Scientific, Biotech Stock Review, Telehealth

Report: My-Cam™ and My-Cardia™ the Ultimate ‘Any-Doctor-Anywhere’ Telehealth Monitoring Application.

New and Updated Report on CB Scientific (CBSC) $1.05. Revolutionary Any-Doctor-Any Where, at Home Heart Rate Monitor, can...

Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.

The 2021 Biotech Six Pack: Stocks We Expect to Double! These are ideas #3 and #4 for the 'Biotech...
Citius, Biotech Stock Review

Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.

The 2021 Biotech Six Pack, Six Stocks We Expect to Double. We're still putting the 2021 list together now,...
Hepion, Biotech Stock Review

Hepion Pharma (HEPA): News Archive

UPDATED CONTINUOUSLY.. 12/31/2020: News, As Huge As It Gets, From Hepion Pharma (HEPA) $2.10. 12/23/2020: Remember...

Latest article

Revive therapeutics

Our Best Risk to Reward Idea Ever?

Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 pack, 12 Biotech Stocks We Expect to...
Immunix Bio

ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.

Demonstrates 100% Completion of Planned Treatment Cycles. Immix Biopharma, Inc. Wed, January 19, 2022. ImmixBio...
Fuqua Professor David Ridley

Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.

Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...